Neurologix, Inc.

FORT LEE, N.J., June 8, 2011 /PRNewswire/ — Neurologix, Inc. (OTCBB: NRGX) announced today several new results from the Company’s successful Phase 2 clinical trial for its novel, investigational gene therapy NLX-P101 for the treatment of Parkinson’s disease (PD) as part of a comprehensive presentation of study findings to the National Institutes of Health (NIH) Recombinant DNA Advisory Committee (RAC). Recently completed analysis of new data showed patients treated with NLX-P101 had significantly increased “ON” times, or periods in which the symptoms of PD are best controlled, compared to sham subjects over the course of 12 months following treatment (p<0.05; ANOVA). Significant reductions in complications due to medical therapy were also seen following treatment with NLX-P101. These new findings, which demonstrate patients treated with NLX-P101 maintained statistically significant, positive, long-term improvements at 12 months, were included in today’s presentation of results from the landmark Phase 2 trial by Matthew J. During, M.D., D.Sc., one of the scientific co-founders of Neurologix. Patients with moderate to advanced PD often suffer from reduced effectiveness of medication, including less time spent each day in the better or “ON” state. The new findings presented today of the NLX-P101 Phase 2 study demonstrated that treatment with the novel gene therapy resulted in an average daily increase of 2.5 hours of “ON” time at 3 months (p<0.01 relative to baseline; t-test) and this increase was sustained at 2.1 hours of greater “ON” time at 12 months (p<0.01 relative to baseline; t-test). There was no significant increase in “ON” time in sham patients at any time point. There was also a significant reduction in complications of medication in the NLX-P101 group at 6 and 12 months following treatment (p<0.01 and p<0.05, respectively; t-test) as measured by Part 4 of the Unified Parkinson’s Disease Rating Scale (UPDRS), with no s ‘/>”/> SOURCE